Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Mississippi for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Mississippi only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Mississippi (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Tammy Young (NPI 1013911668)

Field	Value
Entity Type	Individual
Organization	Tammy Young
Address	1227 N State St
City	Jackson
State	MS
ZIP	39202
Taxonomy	Medical Oncology Physician
NPI Enumerated	June 10, 2005

Payer Source	Total Paid
Medicare	$5.1M
Medicaid	$0

Key Findings

This provider is an infusion-focused medical oncology practice: the top revenue-driving items are high-cost oncology injectables and chemotherapy administration codes, with J9271 (pembrolizumab) generating $1.6M revenue (31.8% of this provider's total Medicare revenue) and J9299 (nivolumab) generating $940.8K revenue (19.1%). Supportive and biologic agents such as J0897 (denosumab, $494.6K, 10.0%) and J2506 (pegfilgrastim, $169.4K) also appear in the top list, and chemotherapy administration codes like 96413 and 96401 are present, signaling a full-service oncology infusion operation rather than a primarily outpatient evaluation practice.

Revenue is highly concentrated: the precomputed top-3 Medicare codes account for 60.9% of this provider's total Medicare revenue, indicating the practice derives the majority of its Medicare income from a small set of high-value oncology injectables. That concentration suggests business sensitivity to utilization or pricing changes for these specific agents.

Payer mix is effectively single-payer: the provider reports $5.1M total Medicare revenue and has no Medicaid billing on file. Because there is no Medicaid activity, commercial and Medicaid exposure cannot be assessed from these data and Medicare dominates the observed revenue stream.

The provider demonstrates above-typical national volumes for several hallmark oncology drugs: J9271 ranks #49 of 1841 providers nationally (97th percentile; notably above typical national volume for this code) and J9299 ranks #33 of 505 providers nationally (94th percentile; notably above typical national volume). These ranks position the provider as a major national participant for key immunotherapy agents rather than a low-volume, local-only operator.

There are multiple statistical outliers in the code mix that reinforce national prominence: J0897 is labeled an "extreme outlier, far above typical national volume" (rank #120 of 10057 providers nationally, 99th percentile) and J2506 is a 100th percentile extreme outlier (rank #3 of 586 providers nationally). In addition, several evaluation/management and infusion codes (for example, 99214 and 96413) are described as extreme outliers or far above typical volume, underscoring unusually high throughput for both visits and chemotherapy administration.

Clinical support services and ancillary testing are present but represent a small share of revenue: lab panels and common phlebotomy codes such as 80053, 85025 and 36415 appear in the top-25 with modest revenue contributions (each under 1% of Medicare revenue), consistent with on-site monitoring and routine labs tied to active infusion services rather than independent pathology volume.

Competitive standing is mixed by code: for several biologic and specialty drug codes this provider ranks in the very high percentiles nationally (e.g., J9271 97th percentile; J0897 99th percentile), indicating a dominant role among peers for those therapies, while for other common oncology or supportive codes the provider’s volumes are described as typical or unremarkable for national peers. This suggests market leadership specifically around certain immunotherapies and supportive biologics rather than across all oncology service lines.

Tenure and continuity: the NPI was enumerated on 2005-06-10 (~21 years ago), indicating long-standing Medicare participation. The extended enrollment period together with the high volumes on key oncology injectables suggests an established infusion practice with sustained use of specific therapy lines over time.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

78 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	36,400	$40	$1.6M
J9299	Injection, nivolumab, 1 mg	39,200	$20	$940.8K
J0897	Injection, denosumab, 1 mg	27,480	$20	$494.6K
J9022	Injection, atezolizumab, 10 mg	6,140	$50	$319.5K
J9311	Injection, rituximab 10 mg and hyaluronidase	7,980	$30	$231.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,610	$80	$219K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	18,600	$10	$186K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	5,090	$30	$173.1K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	2,170	$80	$169.4K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	3,830	$30	$99.5K

Showing 1–10 of 78

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 78 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Mississippi Distribution

Tammy Young — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Mississippi

Full comparison — all codes billed, vs. state median

78 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	10	16,700	$40	$1M
J9299	2	10	21,120	$20	$569.7K
J1568	4	10	7,420	$30	$393.8K
J9022	1	10	6,140	$50	$318.2K
J9311	1	10	7,080	$30	$195.5K
J1449	6	10	4,160	$30	$149.3K
J9264	2	10	14,550	$10	$145.7K
J0897	1	110	3,030	$20	$95.7K
J2506	2	10	910	$80	$91.5K
Q5117	1	10	3,050	$20	$68.6K

Showing 1–10 of 78

Related Providers

Other providers that share a Tax Identification Number (TIN) with Tammy Young, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Guangzhi Qu	MS	Hematology & Oncology Physician	$9.1M	$0
Justin Baker	MS	Hematology & Oncology Physician	$4.1M	$0
Nicole Cleveland	MS	Medical Oncology Physician	$2.8M	$0
Thomas Williamson	NC	Hematology & Oncology Physician	$2.4M	$0
Manubhai Patel	MS	Medical Oncology Physician	$1.9M	$0
Elizabeth Herrington	MS	Medical Oncology Physician	$1.9M	$0
Natale Sheehan	MS	Medical Oncology Physician	$1.4M	$0
Bobby Graham	MS	Hospice and Palliative Medicine (Internal Medicine) Physician	$143.8K	$0
Donald Tisdale	MS	Family Nurse Practitioner	$113.4K	$0
Meaghan Johnson	MS	Family Nurse Practitioner	$98.5K	$0

Nearby Providers

Other providers in the same ZIP code as Tammy Young, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mississippi Behavioral Health Services, LLC	MS	Community/Behavioral Health Agency	$0	$72.8M
Mississippi Baptist Medical Center, Inc.	MS	General Acute Care Hospital	$0	$42M
Mississippi Children's Home Society - Mypac	MS	Mental Illness Community Based Residential Treatment Facility	$0	$26.5M
Medical Foundation Of Central Mississippi, Inc.	MS	Internal Medicine Physician	$0	$7.5M
James Brown	MS	Retina Specialist (Ophthalmology) Physician	$5.4M	$8.9K
Michael Borne	MS	Retina Specialist (Ophthalmology) Physician	$4.5M	$1.8K
Mississippi Physicians, LLP	MS	Emergency Medicine Physician	$0	$4.2M
Mae Physicians Surgery Center, LLC	MS	Ambulatory Surgical Clinic/Center	$3.4M	$114.8K
Chelsea Cockrell	MS	Family Nurse Practitioner	$3M	$0
Mississippi Urology Outpatient Surgery Center, LLC	MS	Ambulatory Surgical Clinic/Center	$1.8M	$9.8K

Tammy Young — Billing Profile & Reimbursement Data

Sign up for Tammy Young — Billing Profile & Reimbursement Data policy alerts

Tammy Young — Billing Profile & Reimbursement Data

Sign up for Tammy Young — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References